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Objective: Interleukin-6 (IL-6), is an inflammatory cytokine
that may influence the pathogenesis of obesity and hyperan-
drogenism. IL-6 exerts its actions through a heterodimeric
receptor consisting of two membrane-bound glycoproteins:
an 80-kDa IL-6 binding unit (IL6R-) and a 130-kDa IL-6
signal transducer (gp130). Genetic variability at these loci
might contribute to explain the development of obesity and
hyperandrogenism.
Research Methods and Procedures: We have evaluated the
possible association of several polymorphisms in the
IL6R- and gp130 genes with obesity and/or hyperandro-
genism in a case-control study involving 143 hyperandro-
genic patients and 45 healthy women from Spain.
Results: A microsatellite CA-repeat polymorphism in the
IL6R- locus was associated with obesity. The frequency of
the common 149-bp allele was markedly increased in obese
women compared with controls when considering patients
and controls as a whole (0.41 vs. 0.29, 2  17.085, p 
0.050). On the other hand, the uncommon Arg148 allele of
the Gly148Arg polymorphism in the gp130 gene was more
frequent in controls compared with hyperandrogenic pa-
tients (0.17 vs. 0.08, 2  5.605, p  0.026). Controls
carrying Arg148 alleles had lower 11-deoxycortisol and
17-hydroxyprogesterone concentrations, a lower response
of androstenedione to 1–24 adrenocorticotropin, and an
almost significant decrease in free testosterone levels, sug-
gesting that Arg148 alleles in the gp130 gene have a pro-
tective effect against androgen excess and adrenal hyperac-
tivity.
Discussion: Polymorphisms in the gp130 and IL6R- loci
influence hyperandrogenism and obesity, respectively. Our
present results further suggest that proinflammatory geno-
types are involved in the pathogenesis of these common
metabolic disorders.
Key words: IL6R-, gp130, insulin resistance, polycystic
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Introduction
Hyperandrogenism and polycystic ovary syndrome
(PCOS)1 are possibly the most common endocrine disorders
in women of fertile age (1). PCOS, defined by endocrine
criteria, is present in 6.5% of women from Spain (2).
Familial aggregation of PCOS and hyperandrogenism pro-
vide evidence suggesting a genetic basis for these disorders
(3). However, their precise genetic mechanisms remain un-
known despite significant efforts.
We have recently hypothesized that inflammatory cyto-
kines may be involved in the pathogenesis of hyperandro-
genism, as has been proposed for insulin resistance, type 2
diabetes, obesity, and the metabolic syndrome (4). These
common genetic disorders might result from adaptive
changes that, from an evolutionary perspective, favor short-
term survival.
Proinflammatory genotypes might have been selected
during evolution because a high cytokine responder pheno-
type may provide survival advantages. Among others, these
inflammatory genotypes and phenotypes may facilitate de-
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fense against injury and infection, and may induce insulin
resistance, preserving glucose for brain metabolism, and
providing defense against starvation during periods of food
shortage. However, these adaptive mechanisms are no
longer beneficial when subjects are exposed to the marked
increase in caloric intake and the sedentary habits associated
with present Western lifestyle, leading to disease.
The rapid maturation of the reproductive axis found in
hyperandrogenic subjects, together with the increase in as-
sertive behavior resulting from increased androgen secre-
tion, might be advantageous during times of environmental
stress (5–7). Also, the relative infertility of hyperandrogenic
women could increase the interval between pregnancies,
decreasing the birth rate and favoring maternal and infant
survival (5).
The recent finding of increased C-reactive protein levels
in women with PCOS (8) suggests that chronic inflamma-
tion might be involved in the pathogenesis of hyperandro-
genic disorders. Moreover, several of our previous studies
supported the association of hyperandrogenism with proin-
flammatory genotypes: 1) the 308A allele in the promoter
of tumor necrosis factor (TNF)- gene is associated with
increased serum androgens in hyperandrogenic and healthy
women independently of obesity and insulin resistance (9);
2) the 196R alleles in exon 6 of the TNFRSF1B gene—
which encodes type 2 TNF receptor—are associated with
hyperandrogenism and PCOS (10); and 3) the 597G and
174G alleles in the promoter of the interleukin-6 (IL-6)
gene, which are in linkage disequilibrium, are associated
with hyperandrogenism (11).
There is also mounting evidence that obesity, which is
frequently found in hyperandrogenic patients (12), is also
associated with proinflammatory genotypes and phenotypes
(13,14). Accordingly, IL-6 seems to influence the patho-
physiology of obesity and the metabolic syndrome (15,16).
Of note, we have recently shown that, considering healthy
and hyperandrogenic women as a whole, those homozygous
for the uncommon597A or174C alleles in the promoter
of the IL-6 gene are protected against the increase in serum
IL-6 induced by obesity (11).
IL-6 exerts its actions through a heterodimeric receptor
consisting of two membrane-bound glycoproteins: an 80-
kDa IL-6 binding unit (IL6R- or gp80) and a 130-kDa IL-6
signal transducer (IL6ST, IL6R-, or gp130). The latter is a
transducer chain shared by other cytokines that is responsi-
ble for signal transduction of the  chain-ligand complex
through the Janus kinase/signal transducer and activator of
transcription pathway (17).
To further delineate the contribution of the IL-6 system
to the pathogenesis of obesity and hyperandrogenism, we
have studied the possible association of these metabolic
disorders with several polymorphisms in the IL6R- and
gp130 loci.
Research Methods and Procedures
Subjects
One hundred forty-three hyperandrogenic patients (age,
24.0  6.5 years; BMI, 28.6  8.0 kg/m2) and 45 healthy
nonhyperandrogenic women (age, 30.8  8.1 years; BMI,
28.1  7.6 kg/m2) were studied. The hyperandrogenic
group was prospectively recruited and included women
complaining of hirsutism and/or hyperandrogenic anovula-
tion. The control group was composed of lean female vol-
unteers and consecutive patients attending the clinical prac-
tice of one of the authors (H.F.E.-M.) for treatment of
obesity. None of the controls had signs or symptoms of
hyperandrogenism, menstrual dysfunction, or history of in-
fertility.
Eighty-eight patients presented with PCOS, defined by
oligo-ovulation, clinical and/or biochemical hyperandro-
genism, and exclusion of hyperprolactinemia (serum
prolactin below 24 g/L); nonclassic congenital adrenal
hyperplasia [adrenocorticotropin-stimulated 17-hydroxy-
progesterone levels below 30 nM (18)]; and androgen-
secreting tumors (19). In these patients, evidence for oligo-
ovulation was provided by chronic oligomenorrhea, by lu-
teal phase progesterone below 12.7 nM, or by basal body
temperature charts.
Fifty-five patients had hyperandrogenic hirsutism, de-
fined by hirsutism, increased serum androgen levels, regular
menstrual cycles, and no definite proof of oligo-ovulation.
Because previous studies by others suggest that PCOS and
hyperandrogenemia cosegregate in hyperandrogenic fami-
lies (3) and because the associations between proinflamma-
tory genotypes and hyperandrogenism were not restricted to
PCOS in our previous studies (10,11), we decided to study
women with PCOS and with hyperandrogenic hirsutism as
a whole.
We excluded women presenting with idiopathic hirsutism
(regular menstrual cycles and normal serum androgen con-
centrations), because previous studies of our group sug-
gested a specific genetic etiology (20).
Data from some patients and controls, regarding different
aspects of the pathophysiology of hirsutism, have been
previously published (9–11,20,21). Particularly, 85 patients
and 25 controls were studied for several polymorphisms in
the promoter of the IL-6 gene (11).
The patients and controls had not taken hormonal medi-
cations, including contraceptive pills, for the last 6 months.
All the subjects were white.
The ethics committee of the Hospital Ramo´n y Cajal
approved the study, and informed consent was obtained
from each patient and control.
Study Protocol and Hormone Profiles
Studies were performed between days 5 and 10 of the
menstrual cycle, or during amenorrhea, after excluding
pregnancy by proper testing. Between 8:00 AM and 9:00 AM,
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after a 12-h overnight fast, an indwelling intravenous line
was placed in a forearm vein, and after 15 to 30 minutes,
basal blood samples were obtained for the measurement of
gp130, total testosterone, dehydroepiandrosterone-sulfate,
luteinizing hormone, follicle-stimulating hormone, estra-
diol, sex hormone-binding globulin, glucose, and insulin.
Immediately after taking basal samples, a 250-g intrave-
nous bolus of 1–24 adrenocorticotropin (Synacthen; Ciba-
Geigy, Basle, Switzerland) was injected, and blood samples
were obtained at 0 and 60 minutes for the measurement of
cortisol, 11-deoxycortisol, 17-hydroxyprogesterone, and
4-androstenedione. The adrenocorticotropin test was not
performed in six control women, but their basal samples
were assayed for serum cortisol and 4-androstenedione in
addition to the basal determinations described above. Sam-
ples were immediately centrifuged, and serum was sepa-
rated and frozen at 20 °C until assayed.
In 84 patients and 35 controls, serum gp130 levels were
measured by enzyme-linked immunosorbent assay kit [Hu-
man Soluble IL-6 Receptor  chain (sgp130); Biosource
International, Camarillo, CA], with a lower limit of detec-
tion of 18.5 pg/mL, and mean intra- and interassay CVs of
4% and 7%, respectively. The technical characteristics of
the assays employed for hormone measurements have been
reported elsewhere (21–23). The free testosterone concen-
tration was calculated from total testosterone and sex hor-
mone-binding globulin concentrations, assuming a serum
albumin concentration of 43 g/L and taking a value of 1 
109 L/mol for the association constant of sex hormone-
binding globulin for total testosterone and a value of 3.6 
104 L/mol for that of albumin for total testosterone (24).
Insulin resistance in the fasting state was estimated from
glucose and insulin levels using the fasting insulin resis-
tance index [FIRI  glucose (mM)  insulin (mU/L)/25]
(25).
DNA Extraction and Genotype Analysis
Genomic DNA was extracted from leukocytes obtained
from whole blood samples using commercial DNA purifi-
cation kits (Wizard Genomic DNA purification kit; Pro-
mega, Madison, WI; and Nucleon BAC C3; Amersham
Pharmacia, Buckinghamshire, UK).
The CA-repeat polymorphism at the IL6R- locus was
amplified by polymerase chain reaction as reported by
Tsukamoto et al. (26), but the forward primer was labeled
with HEX fluorescent dye (Table 1). Each polymerase chain
reaction product was diluted individually and mixed with
deionized formamide and an N,N,N,N-tetramethyl-6-carboxy-
rhodamine fluorescent molecular weight marker as an in-
ternal control (Applied Biosystems, Foster City, CA). Each
sample was denatured for 10 minutes at 96 °C and analyzed
by capillary electrophoresis on an ABI 310A automated
sequencer (Applied Biosystems). The size of the amplified
fragments was determined by using the GeneScan software
(Applied Biosystems). To obtain further confirmation about
the location of this polymorphism, we sequenced the am-
plified fragment from one subject homozygous for the most
common allele, and the sequence enclosing the CA-repeat
polymorphism corresponded to that of intron 8 of IL6R-.
A broad screening for polymorphisms in the gp130 was
performed in at least 60 chromosomes (from 15 patients and
15 controls). The following polymorphisms in the gp130
Table 1. Primers and conditions for polymerase chain reaction, amplification, and size of the amplified fragments
Gene Primers
Annealing
temperature
Mg2
(mM) Size (bp)
IL6R- Forward: HEX-5-GGC AAC CGA GCA AGA CTC TC-3 56°C 1.5 149 to 167
Reverse: 5-GCG AGG ACA GAA GAT TTG TC-3
gp130
Val8Leu Forward: 5-TTT AGA AAC ACA GCT ACA GC-3 48°C 2.0 155
Reverse: 5-GAT AGG GTA TTT CAT GAA CC-3
Ser122Ser Forward: 5-TAT GGA ATC ACA ATA ATT CC-3* 56°C 1.5 121
Reverse: 5-TTT AAA AAC CAA ACA TGT CC-3
Gly139Gly,
Lys140Asn,
and Gly148Arg Forward: 5-TGC CTC CAG AAA AAC CTA AA-3 56°C 1.5 203
Reverse: 5-CAT TCA GAT TTT AAA GTG AAG-3
Val392Asp Forward: 5-AGT TTC AGA GAT GCA TTA GC-3 56°C 1.5 149
Reverse: 5-CAT TTG CTT CTA TTT CCA CG-3†
Bold letters were introduced to create a *BstNI restriction site and a †MaeIII restriction site.
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gene were studied: 1) two conservative transitions at codons
122 (TCA to TCG change) and 139 (GGG to GGA) (27,28);
2) two nonconservative substitutions converting Lys to Asn
(AAG to AAC) and Gly to Arg (GGT to CGT) at codons
140 and 148 (27,28), respectively; and 3) two different
nonconservative changes transforming Val to Leu (GTA to
CTA) at codon 8, and converting Val to Asp (GTT to GAT)
at codon 392 (contig accession NT016864, dbSNP
rs1063560 and dbSNP rs10180, respectively; http://www.
ncbi.nlm.nih.gov/SNP/).
The gp130 polymorphisms were screened by restriction
fragment length polymorphism analysis with the following
endonuclease restriction enzymes: BstNI for codon 122,
MboII for codons 139 and 140, Sau3AI for codon 148, MaeI
for codon 8, and MaeIII for codon 392.
Amplifications were performed in an automated thermo-
cycler (Gene Amp PCR System 2400; Applied Biosystems).
Primers, final concentration of Mg2	, and annealing tem-
peratures are summarized in Table 1.
Finally, the 174G/C polymorphism in the promoter of
the IL-6 gene, which we found to be associated with hy-
perandrogenism in a subset of these patients and controls,
was analyzed in the extended series as previously reported
(11), to evaluate a possible collaborative effect of this
variant with the gp130 polymorphism studied here.
Statistical Analysis
Results are expressed as means  SD unless otherwise
stated. The Kolmogorov-Smirnov statistic was applied to
continuous variables. Logarithmic transformation was ap-
plied as needed to ensure normal distribution of the vari-
ables. Unpaired t tests, one-way ANOVA followed by the
least significant difference test, and analysis of covariance
were used to compare the central tendencies of the different
groups as needed. To evaluate the association between
discontinuous variables, we used the 2 test and Fisher’s
exact test as appropriate.
Logistic regression was used to analyze the Gly148Arg
polymorphism in the gp130 gene and the 174G/C poly-
morphism in the promoter of the IL-6 gene and the interac-
tion of both genomic variants, as predictive factors for
hyperandrogenism in our model. The backward likelihood-
ratio test was used as the method for variable selection (29).
Analyses were performed using SPSS 10 for the Macintosh
(SPSS Inc., Chicago, IL). p  0.05 was considered statis-
tically significant.
Results
Clinical, Biochemical, and Hormonal Variables
The comparison of clinical, biochemical, and hormonal
variables between hyperandrogenic patients and controls is
shown in Table 2. Soluble gp130 concentrations were not
different in patients and controls. As expected, hyperandro-
genic patients presented with increased hirsutism scores,
serum free and total testosterone levels, and dehydroepi-
androsterone concentrations. Basal and adrenocorticotrop-
in-stimulated 17-hydroxyprogesterone and androstenedione
concentrations and basal 11-deoxycortisol levels were also
higher in patients compared with controls, whereas sex
hormone-binding globulin and estradiol levels were de-
creased in patients compared with controls. Fasting insulin
levels and the fasting insulin resistance index were in-
creased in patients compared with controls. No differences
were observed in fasting glucose, cortisol, and gonadotropin
concentrations.
Polymorphisms in the gp130 Gene
Six different polymorphisms were studied in the gp130
gene as stated above. We did not observe any variant in
codons 8, 122, 139, 140, and 392 in the initial screening of
60 chromosomes from 15 patients and 15 controls, and
therefore, we did not extend these analyses to include all the
experimental subjects.
On the contrary, we found a high degree of heterozygos-
ity in the Gly148Arg polymorphism at codon 148. The
frequency of the uncommon Arg148 allele in the whole
population was 0.10, and the Arg148 allele was more fre-
quent in controls (0.17) compared with hyperandrogenic
patients (0.08; 2  5.605, p  0.026). Of note, the same
results were found when restricting the analysis to the
subgroup of PCOS patients (0.17 in controls vs. 0.08 in
PCOS patients, 2  4.653, p  0.038).
One patient and one control were homozygous for
Arg148 alleles. Considering subjects homozygous and het-
erozygous for 148 alleles as a whole, carriers of one or two
Arg148 alleles were more frequent in the controls compared
with the hyperandrogenic group (0.31 vs. 0.15, 2  5.468,
p  0.029).
Because the frequencies of Arg148 alleles was different
in patients and in controls and to avoid ascertainment bias,
the influence of having one or two Arg148 alleles on clin-
ical and biochemical variables was studied separately in
patients and in controls (Table 3). We found that, compared
with controls homozygous for Gly148 alleles, those carry-
ing Arg148 alleles had lower basal 11-deoxycortisol and
17-hydroxyprogesterone concentrations, a decreased re-
sponse of androstenedione to adrenocorticotropin, and an
almost significant decrease in free testosterone levels. No
differences were found in the patients with the Gly148Arg
genotype.
Logistic regression was used to analyze the possibility of
a collaborative effect between the Gly148Arg polymor-
phism in the gp130 gene and the 174G/C polymorphism
in the promoter of the IL-6 gene in the pathophysiology of
hyperandrogenism. The association of the 174G alleles in
the promoter of the IL-6 gene with hyperandrogenism was
confirmed in the extended series presented here. Con-
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versely, homozygosity for 174C alleles was more fre-
quent in controls compared with hyperandrogenic patients
(26.7% of controls vs. 11.4% of patients, 2  6.156, p 
0.018).
The finding that carriers of Arg148 alleles of the gp130
gene and that homozygosity for 174C alleles in the pro-
moter of the IL-6 gene were more frequent in controls
compared with hyperandrogenic patients suggested a pro-
tective effect of these variants against the development of
hyperandrogenism.
The dependent variable of the logistic regression model
was coded 1 for hyperandrogenic patients and 0 for healthy
controls. Carrying Arg148 alleles of the gp130 gene, ho-
mozygosity for 174C alleles in the promoter of the IL-6
gene, and the interaction of both were introduced as inde-
pendent variables.
Independent variables explained only 8.1% (Nagel-
kerke’s R2  0.081) of the variation of the dependent
variable (29), suggesting a modest contribution of the
Gly148Arg polymorphism in the gp130 gene and the
174G/C polymorphism in the promoter of the IL-6 gene to
the pathophysiology of hyperandrogenism.
Agreeing with their hypothetical protective influence,
carrying Arg148 alleles of the gp130 gene (odds ratio for
hyperandrogenism 0.404, p  0.026) and homozygosity for
174C alleles in the promoter of the IL-6 gene (odds ratio
for hyperandrogenism 0.368, p  0.022) predicted signifi-
cantly absence of hyperandrogenism (i.e., being a healthy
control). However, no significant interaction was found
between both polymorphisms (p  0.247).
Polymorphism in the IL6R- Gene
As stated above, we also studied a microsatellite CA-
repeat polymorphism in the IL6R- gene. We detected 10
alleles with sizes ranging from 149 to 167 bp in the 184
women (43 controls and 141 patients) who were genotyped
for this polymorphism. Their size and frequencies are
shown in Table 4. The distribution of alleles was not dif-
ferent in hyperandrogenic patients compared with healthy
controls (Table 4).
Because in previous studies we found that serum IL-6
concentrations are increased in obese women (11), we stud-
ied a possible influence of the polymorphisms of the
IL6R- polymorphism with obesity (defined by a BMI 
Table 2. Clinical and biochemical variables in hyperandrogenic patients and controls
Patients (n) Controls (n) p
Hirsutism score 14.1 6.4 (143) 1.5 1.4 (45) 0.001
Soluble gp130 (pg/mL) 225 47 (84) 239 62 (35) 0.483
Total testosterone (nM) 2.5 0.9 (143) 1.4 0.5 (45) 0.001
Free testosterone (pM) 47 27 (143) 19 8 (45) 0.001
Sex hormone-binding globulin (nM) 35 19 (143) 59 27 (45) 0.001
Dehydroepiandrosterone-sulfate (M) 7.8 3.8 (143) 4.9 2.4 (45) 0.020
Basal cortisol (nM) 437 164 (143) 403 137 (42) 0.658
ACTH-stimulated cortisol (nM) 858 190 (143) 861 185 (36) 0.477
Basal 11-deoxycortisol (nM) 8.0 4.6 (143) 5.5 2.6 (36) 0.050
ACTH-stimulated 11-deoxycortisol (nM) 13.3 5.5 (143) 12.1 4.9 (36) 0.678
Basal androstenedione (nM) 13.9 5.0 (143) 9.0 3.1 (45) 0.001
ACTH-stimulated androstenedione (nM) 17.6 5.5 (143) 12.2 4.2 (36) 0.001
Basal 17-hydroxyprogesterone (nM) 3.4 2.1 (143) 2.1 1.0 (39) 0.020
ACTH-stimulated 17-hydroxyprogesterone (nM) 9.8 5.3 (143) 7.6 3.3 (36) 0.068
Luteinizing hormone (IU/L) 5.6 3.4 (143) 5.2 3.6 (45) 0.191
Follicle stimulating hormone (IU/L) 5.6 3.5 (143) 6.5 6.6 (45) 0.977
Estradiol (pM) 166 98 (143) 254 172 (45) 0.020
Fasting insulin (pM) 103 59 (143) 78 45 (45) 0.005
Fasting glucose (mM) 4.7 0.6 (143) 4.9 0.5 (45) 0.781
FIRI (mmol  mU) 2.9  1.9 (143) 2.2 1.4 (45) 0.010
Data are means  SD. Because patients were younger compared with controls, analysis were corrected for the difference in age by analysis
of covariance. Values in parentheses indicate the number of subjects included in each comparison.
FIRI, fasting insulin resistance index.
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Table 3. Influence of the Gly148Arg polymorphism in the gp130 gene on clinical and biochemical variables, in
hyperandrogenic patients and controls separately
Controls Patients
Gly148Gly (n)
Gly148Arg

Arg148Arg (n) p Gly148Gly (n)
Gly148Arg

Arg148Arg (n) p
Age (years) 29.5 7.9 (31) 33.8 8.1 (14) 0.094 23.8 6.4 (121) 25.2 6.8 (22) 0.375
Body mass index (kg/m2) 28.7 8.1 (31) 26.8 6.3 (14) 0.503 28.3 7.8 (121) 30.3 8.9 (22) 0.279
Hirsutism score 1.6 1.4 (31) 1.5 1.6 (14) 0.820 14.1 6.2 (121) 14.4 7.6 (22) 0.817
Soluble gp130 (pg/mL) 243 70 (23) 232 45 (12) 0.627 225 48 (71) 225 40 (13) 0.979
Total testosterone (nM) 1.5 0.5 (31) 1.3 0.4 (14) 0.186 2.4 0.9 (121) 2.6 1.2 (22) 0.313
Free testosterone (pM) 21 9 (31) 16  7 (14) 0.051 46 23 (121) 53 43 (22) 0.469
Sex hormone-binding
globulin (nM) 55 27 (31) 67 25 (14) 0.132 35 19 (121) 36 21 (22) 0.927
Dehydroepiandrosterone-
sulfate (M) 5.1 2.4 (31) 4.6 2.5 (14) 0.536 7.9 3.9 (121) 7.3 3.3 (22) 0.461
Basal cortisol (nM) 403 155 (29) 403 94 (13) 0.978 447 166 (121) 384 148 (22) 0.097
ACTH-stimulated cortisol
(nM) 869 218 (24) 847 102 (12) 0.827 867 194 (121) 811 164 (22) 0.212
Basal 11-deoxycortisol
(nM) 6.1 2.6 (24) 4.3 2.0 (12) 0.025 8.0 4.5 (121) 8.1 5.5 (22) 0.764
ACTH-stimulated 11-
deoxycortisol (nM) 12.4 5.2 (24) 11.3 4.0 (12) 0.575 13.2 5.4 (121) 13.9 6.4 (22) 0.498
Basal androstenedione
(nM) 9.5 3.2 (31) 8.0 2.9 (14) 0.131 14.1 5.1 (121) 12.9 4.0 (22) 0.357
ACTH-stimulated
androstenedione (nM) 13.3 4.5 (24) 10.5 3.5 (12) 0.001 17.7 5.6 (121) 17.1 5.0 (22) 0.692
Basal 17-
hydroxyprogesterone
(nM) 2.3 1.1 (26) 1.6 0.6 (13) 0.020 3.5 2.2 (121) 2.8 1.7 (22) 0.159
ACTH-stimulated 17-
hydroxyprogesterone
(nM) 8.2 3.9 (24) 6.7 2.4 (12) 0.172 10.0 5.5 (121) 9.0 3.5 (22) 0.505
Luteinizing hormone
(IU/L) 5.6 3.9 (31) 4.5 3.0 (14) 0.434 5.6 3.4 (121) 5.5 3.3 (22) 0.884
Follicle stimulating
hormone (IU/L) 6.8 8.1 (31) 5.8 1.7 (14) 0.836 5.7 3.7 (121) 5.5 2.0 (22) 0.435
Estradiol (pM) 255 188 (31) 252 146 (14) 0.707 168 101 (121) 151 82 (22) 0.439
Fasting insulin (pM) 84 47 (31) 64 36 (14) 0.244 103 57 (121) 100 71 (22) 0.368
Fasting glucose (mM) 4.8 0.6 (31) 4.8 0.5 (14) 0.899 4.7 0.6 (121) 4.7 0.4 (22) 0.929
FIRI (mmol  mU/L2) 2.4 1.5 (31) 1.8 1.0 (14) 0.293 2.9 1.9 (121) 2.8 2.2 (22) 0.436
Data are means  SD. The mean values were compared by unpaired t tests, separately in the control group and in the patients. The
homogeneity of the variances was evaluated by Levene’s tests, and the results were interpreted accordingly. Values in parentheses indicate
the number of subjects included in each comparison.
FIRI, fasting insulin resistance index.
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25 kg/m2). The frequency of the common 149-bp allele was
markedly increased in obese women compared with lean
women when considering patients and controls as a whole
(Table 4). In agreement, homozygosity for 149 alleles was
much more prevalent in the obese group compared with the
lean group (Table 5). Accordingly, subjects homozygous for
149 alleles presented with increased BMI (33.2  9.2
kg/m2) compared with carriers of 149 alleles (28.2  6.9
kg/m2) and carriers of non-149 alleles (27.5  8.1 kg/m2;
one-way ANOVA followed by LSD test, F  5.049, p 
0.007). On the contrary, IL6R- genotypes were distributed
similarly in hyperandrogenic patients and healthy controls
(Table 5).
Discussion
During the past years, significant efforts have been di-
rected toward the elucidation of the genetic mechanisms
underlying the pathogenesis of hyperandrogenism and
PCOS. Although the initial studies suggested a model in
which a few genes played a major role in PCOS inheritance
(30), the emerging picture suggests that hyperandrogenism
arises from the interaction of multiple genomic variants
with environmental factors such as obesity and a sedentary
lifestyle.
Certain genomic variants leading to common metabolic
disorders might have provided a survival advantage during
the process of natural selection (4). Witchel et al. (5) re-
cently proposed that hyperandrogenism in women also pro-
vides a survival advantage, and we recently hypothesized
that certain proinflammatory genotypes, previously known
to influence the pathogenesis of insulin resistance, obesity,
and the metabolic syndrome (4), may also be related to the
pathogenesis of hyperandrogenism and PCOS (9,11). This
hypothesis may also provide an explanation to the well-
Table 4. Distribution of the different alleles of the IL6R- dinucleotide polymorphism in the whole population
(n  184), in hyperandrogenic patients (n  141) compared with healthy controls (n  43), and in lean women
(n  76) compared with obese women (n  108)
IL6R alleles Whole group Healthy women Hyperandrogenic patients Lean subjects Obese subjects
149 132 (0.36) 35 (0.41) 97 (0.34) 43 (0.28) 89 (0.41)
151 21 (0.06) 3 (0.04) 18 (0.06) 7 (0.05) 14 (0.07)
153 9 (0.02) 1 (0.01) 8 (0.03) 7 (0.05) 2 (0.01)
155 34 (0.09) 7 (0.08) 27 (0.10) 10 (0.07) 24 (0.11)
157 43 (0.12) 10 (0.12) 33 (0.12) 23 (0.15) 20 (0.09)
159 30 (0.08) 6 (0.07) 24 (0.09) 14 (0.09) 16 (0.07)
161 35 (0.10) 8 (0.09) 27 (0.10) 18 (0.12) 17 (0.08)
163 29 (0.08) 8 (0.09) 21 (0.07) 13 (0.08) 16 (0.07)
165 26 (0.07) 6 (0.07) 20 (0.07) 13 (0.08) 13 (0.06)
167 9 (0.02) 2 (0.02) 7 (0.03) 4 (0.03) 5 (0.02)
Statistics 2  3.090, p  0.961 2  17.085, p  0.050
Data are number of alleles. Values in parentheses are the frequencies within each group. Obesity was defined by a BMI 25 kg/m2.
Table 5. Association of the IL6R- genotype with obesity
IL6R- genotype
Healthy
women
(n  43)
Hyperandrogenic
patients
(n  141)
Lean
women
(n  76)
Obese
women
(n  108)
149/149 (n  24) 7 17 3 21
149/other (n  84) 21 63 37 47
Other/other (n  76) 15 61 36 40
Statistics 2  1.135, p  0.567 2  9.627, p  0.010
Data are number of subjects. Subjects were grouped depending on the presence or absence of 149 alleles.
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known association of hyperandrogenism and PCOS with
insulin resistance (31) and obesity (12) and to the cosegre-
gation of hyperandrogenemia with insulin resistance within
families of PCOS probands, irrespective to the presence or
absence of menstrual irregularity (32).
We have reported that the308A allele of the308 G/A
polymorphism in the promoter of the TNF- gene was
associated with increased serum androgen levels in a mixed
population of hyperandrogenic patients and nonhyperandro-
genic controls, although the frequency of this allele was
similar in hyperandrogenic and nonhyperandrogenic women
(9). More recently, our recent finding of an association
between the uncommon 196Arg allele in the TNFRSF1B
gene—which encodes type 2 TNF receptor—with hyperan-
drogenism and PCOS (10) further suggest an involvement
of the TNF- axis on hyperandrogenic disorders.
Also, we have studied the possible involvement of IL-6,
which is the most endocrine of inflammatory cytokines
(33), on the pathogenesis of hyperandrogenism. Two single
nucleotide polymorphisms in the promoter of the IL-6 gene,
which are in disequilibrium linkage, were associated with
hyperandrogenism. The common G alleles of the 597G/A
and 174G/C polymorphisms were more frequent in hy-
perandrogenic patients compared with controls. Also, in
healthy controls, G alleles of the 597G/A and of
174G/C polymorphisms induced a graded increase in
serum IL-6, cortisol, 11-deoxycortisol, and 17-hydroxypro-
gesterone concentrations, and a tendency toward an increase
in testosterone concentrations (11). Conversely, these levels
were lower in subjects homozygous for 597A and for
174C alleles, suggesting a protective role against in-
creased IL-6 and adrenal steroid secretion for these genomic
variants. Of note, this protective effect against the increase
in IL-6 levels was more evident in obese subjects (11), who
usually have increased serum IL-6 concentrations compared
with lean subjects (33).
Our present results regarding the IL-6 receptor complex
further expand the notion that proinflammatory genotypes
influence the pathogenesis of hyperandrogenism and obe-
sity. On the one hand, the Gly148Arg polymorphism in the
gp130 gene was associated with hyperandrogenism, Gly148
alleles being more frequent in patients and Arg148 alleles
more frequent in controls. On the other, controls carrying
Arg148 alleles presented with lower basal 11-deoxycortisol
and 17-hydroxyprogesterone concentrations, a decreased
response of androstenedione to adrenocorticotropin stimu-
lation, and an almost significant decrease in free testoster-
one levels. However, these hormonal differences should be
considered with caution because of the possibility of a type
II error, as a large number of clinical and biochemical
variables were included in the analysis, and also because of
the lack of similar findings in the patients. Also, the results
of the logistic regression analysis further suggests that
Arg148 alleles play a protective role against androgen ex-
cess, as we recently suggested also for 597A and 174C
alleles of the IL-6 gene (11).
However, we have not been able to demonstrate a signif-
icant collaborative effect of the Gly148Arg polymorphism
in the gp130 gene and of the174G/C polymorphism in the
promoter of IL-6 gene, on the development of hyperandro-
genism, although this demonstration may require the study
of both polymorphisms in a larger series of hyperandro-
genism patients and healthy controls.
Furthermore, the microsatellite CA-repeat polymorphism
in the IL6R- gene also influenced obesity, irrespective of
the presence or absence of hyperandrogenism. The common
149-bp allele was more frequent in obese subjects compared
with lean women, especially when present in homozygosis.
Of note, IL-6 is secreted by adipose tissue (34), and adipose
tissue IL-6 content correlates with insulin resistance (35),
suggesting that IL-6 plays an important role on the patho-
genesis of the metabolic syndrome (14). In this context, it is
not surprising that genomic variation at the IL6R- locus
might also be involved in the pathogenesis of obesity.
However, the functional consequences of the polymor-
phisms in gp130 and IL6R- on the transduction of the IL-6
signal are not known at present. Therefore, the association
of the Gly148Arg polymorphism in the gp130 gene with
hyperandrogenism and the association of the CA-repeat
polymorphism in the IL6R- gene with obesity found in our
present study should be considered carefully because a clear
pathogenic link is still lacking.
The fact that the common alleles of the polymorphisms
studied here are those associated with disease (hyperandro-
genism or obesity) permit us to speculate that these genomic
variants were selected during evolution because of a previ-
ous survival advantage, but now have deleterious conse-
quences because these mechanisms were beneficial only in
a hostile environment of food shortage and starvation. This
mechanism also contributes to explain the high prevalence
of metabolic disorders such as obesity, type 2 diabetes,
hypertension, and atherosclerosis reported in most Western
areas.
Moreover, based on our present and previous findings in
hyperandrogenic women, we can also speculate that the
uncommon genomic variants in genes of the IL-6 axis that
are associated with healthy controls may protect these in-
dividuals who lack these metabolic adaptive mechanisms
that nowadays are not beneficial because life expectancy is
increased and access to food is not restricted.
Therefore, the pathogenesis of metabolic disorders may
be influenced by complex interactions between predispos-
ing and protective genomic variants with environmental
factors. Because the latter are different depending on ethnic
and geographic factors, the genomic variants resulting in
metabolic disorders may also be different depending on
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these factors, explaining the frequent discrepancies of stud-
ies regarding the genetic basis of complex metabolic disor-
ders.
In summary, we here report novel associations between
hyperandrogenism and the Gly148Arg polymorphism in the
gp130 gene and between obesity and the CA-repeat poly-
morphism in the IL6R- gene, further suggesting that proin-
flammatory genotypes are involved in the pathogenesis of
these common metabolic disorders.
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